



Conference Programme

Program Sponsored by 
LALLEMAND HEALTH SOLUTIONS

Day 1 - Tuesday, March 12th

14:00-14:55 **Registration & Welcome Coffee**  

14:55-15:00 **Welcome Note**



Sandrine Claus
President, Pharmabiotic Research Institute

Fundamental Science Session

Chaired by Bruno Pot 

15:00-15:25



Gut Bioengineered Models to Study Host-microbiome Direct Interactions

Catherine Daniel
Senior Researcher/Principal Investigator, Institut Pasteur Lille

15:25-15:50



A Novel Humanised Gut-brain Axis Model

Julia Rode
Associate Senior Lecturer, School of Medical Sciences, Örebro University

15:50-16:15



Interpretable 'White box' Machine Learning for Biomedical Applications

Stephen Smith
Professor in the School of Physics, Engineering and Technology, University of York

16:15-16:40



Gamma Irradiation for the Preparation of Non-viable Microbial Biomasses

Simone Guglielmetti
Professor, Università degli Studi di Milano-Bicocca

16:40-17:05



Enterosignatures Allow for Generalized Classification of Abnormal Gut Microbiomes

Falk Hildebrand
Group Leader, Quadram Institute Bioscience/Earlham Institute

17:05-17:30



Remote Control of Immune Surveillance by the Gut Microbiota

Mathias Chamailard
Head of Laboratory Inflammasome and Ion Channels, Inserm

Day 2 - Wednesday, March 13th

08:00-09:00 **Welcome Coffee**



Discovery & Preclinical Session

Chaired by Sandrine Claus



09:00-09:20



In Vitro Approach to Study Microbiota-host Interaction in Health and Diseases

Hervé Blottière

Scientific Director, MetaGenoPolisINRAE/Co-Founder and Scientific Advisor, NovoBiome

09:20-09:40



Novel Insights into Host-Microbiota Interactions via Gut-on-a-Chip

Ostaizka Aizpurua Arrieta

Assistant Professor, Section for Hologenomics, Globe Institute, University of Copenhagen

09:40-10:00



BM109, A First-In-Class Microbiome Therapeutic for TMAO-lowering Therapy: Implications for Treatment of Cardiovascular Disorder and Chronic Kidney Disease

Sang Sun Yoon

Professor of Microbiology, Yonsei University College of Medicine/CEO, BioMe Inc

10:00-10:20



Enabling Immunotherapy Responses in Solid Tumours Through Live Biotherapeutics

Pedro Correia de Sampaio

Co-founder and CEO, Neobe Therapeutics

10:20-11:00 **Coffee Break**



Pharmacomicrobiomics Session

Chaired by Michael Zimmermann



11:00-11:20



Identifying Gut Microbiota Contributions to Drug Metabolism and Toxicity

Michael Zimmermann

Group Leader, EMBL Heidelberg

11:20-11:40



Gut Microbiome Integration in Drug Discovery and Development of Small Molecules

Patrick Jimonet

Health Innovation Project Leader - Microbiome, Medicen Paris Region

11:40-12:00



Emulating the Gut-liver Axis: Dissecting the Microbiome's Effect on Drug Metabolism Using Multi-organ-on-chip Models

Mara Lucchetti

Postdoctoral Researcher, University of Luxembourg

12:00-12:20



Secretory IgA Amplification to Improve Gut Fitness in Cancer Immunotherapy

Fabio Grassi

Chairman, MV Biotherapeutics

12:20-13:40 **Lunch**



In-Human Clinical Trials Session

Chaired by Françoise Le Vacon



13:40-14:00



The MOM Study: Pioneering a New Probiotic Formula to Support a Healthy Pregnancy and the Newborn Health

Sylvie Binda

R&D Vice President, Lallemand

14:00-14:20



Clinical and Mechanistic Insights from Phase 2a Studies with Optimized Consortia Therapeutic MH002 in Ulcerative Colitis and Pouchitis

Katja Conrath
CSO, MRM Health

14:20-14:40



Efficacy and Mode of Action of IMB002 for Inflammatory Disorders

Sin-hyeog Im
Chief Executive Officer, ImmunoBiome Inc
Professor, Pohang University of Science and Technology

14:40-15:00



Engineering the Skin Microbiome for Precision Dermatology

Travis Whitfill
Chief Operating Officer, Azitra

15:00-15:20



Potential Uses of *Faecalibacterium prausnitzii* in Human Health

Philippe Langella
Research Director, INRA/Co-founder, Exeliom Biosciences

15:20-15:50



Biomica & Biose Industrie : The Clinical Journey of a Multi-strain LBP

Shiri Meshner
VP R&D, Biomica



Claire Derlot
Chief Business Officer, Biose Industrie

15:50-16:20

Coffee Break



16:20-16:40



Start-up Clinical Development of Microbiome-based Therapeutic Products

Jelle Klein
Medical Director, SGS Quay Pharma

16:40-17:00



Phage Therapy in Belgium

Jean-Paul Pirnay
Managing Director, Queen Astrid Military Hospital

17:00-17:20



Lactobacillus for Delivery of Chemokines - Clinical and RnD Update

Evelina Vågesjö
CEO and Co-founder, ILYA Pharma

17:20-17:45

Panel Discussion: Clinical Design & Methodology

Moderated by
Françoise Le Vacon



Jean-Paul Pirnay
Managing Director, Queen Astrid Military Hospital



Evelina Vågesjö
CEO and Co-founder, ILYA Pharma



Travis Whitfill
Chief Operating Officer, Azitra



Shiri Meshner
VP R&D, Biomica

Day 3 - Thursday, March 14th

08:30-09:00 **Welcome Coffee**



Microbiome Regulatory Science Considerations & Updates

Chaired by Yolanda Sanz



09:00-09:25



Regulatory Science to Accelerate Market Access

Chrysi Sergaki
Microbiome Group Leader, MHRA

09:25-09:50



EFSA Risk Assessment of Microorganisms Intentionally Added to the Food Chain

Elisa Pettenati
Scientific Officer, EFSA

09:50-10:15



The Human Microbiome Project: Maximising the Impact of European Microbiome Research and Innovation by Ensuring Coherence and Harmony in the Way Microbiome Research is and Will be Performed

Emmanuelle Maguin
Research Director, INRAE

10:15-10:40



Developments in the European Regulatory Landscape: Understanding the Impact of the New SoHO Regulation on Microbiome Innovations

Celine Druart
Executive Director, Pharmabiotic Research Institute

10:40-11:15

Regulatory Science Panel Discussion

Chaired by Yolanda Sanz



Chrysi Sergaki
Microbiome Group Leader, MHRA



Celine Druart
Executive Director, Pharmabiotic Research Institut



Sophie Mathys
Head Regulatory & Quality, PharmaBiome

11:15-11:45

Coffee Break



Innovation Showcase

Chaired by Joseph Simmons



11:45-11:55



Characterisation of the Human Small Intestinal Microbiome Using an Innovative Ingestible Medical Device

Alexandre Tronel
PhD Student, Pelican Health

11:55-12:05



From Benchtop to Biotherapeutic Product: *Dolosigranulum pigrum* AMBR11 for Respiratory Health

Ilke de Broek

Postdoctoral Researcher, University of Antwerp

12:05-12:15



Skin Modulation Through Microbiome Engineering

Marc Güell

Research Professor, Institutió Catalana de Recerca i Estudis Avançats (ICREA)

Sponsors 2024



LALLEMAND HEALTH SOLUTIONS



Your global CDMO for Microbiome Therapeutics



The Beauty of Science is to Make Things Simple



Quadram Institute
Science • Health • Food • Innovation